NATAP: PEGASYS + Ribavirin: New England Journal Study
- NATAP - www.natap.org
PEGASYS + Ribavirin: New England Journal Study
Here is a more detailed report I wrote following the DDW Conference
presentation of this study by Mike fried, MD, the chief study
investigator. In addition, what is not in this report was the results
broken down by genotype and viral load so here it is. For genotype 1
with >2 million viral load pegasys+RBV resulted in 41% SVR vs 33% for
IFN+RBV. For genotype 2 there was not much difference between high or
low viral load: >2 million -74% SVR for Pegasys/RBV vs 59% SVR for
IFN/RBV; <2 million - 81% SVR for Pegasys/RBv vs 65% SVR for IFN/RBV.
Pegylated (40kDa) Interferon Alfa-2a (Pegasys) in Combination With
Ribavirin: efficacy and Safety Results From a Phase III Randomized,
Actively Controlled Multicenter Study
Do you Yahoo!?
New DSL Internet Access from SBC & Yahoo!